Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiology of the Heart: The Cardiac Cycle01:18

Physiology of the Heart: The Cardiac Cycle

9.5K
The cardiac cycle describes the events from one heartbeat to the next. It includes three main phases: diastole, atrial systole, and ventricular systole, all driven by changes in chamber pressures and the function of heart valves.
Diastole: The Relaxation Phase
During diastole, all four heart chambers relax. The atrioventricular (AV) valves open, and the semilunar valves close. This phase sees the lowest chamber pressures, promoting ventricular filling. Venous blood enters the heart through the...
9.5K
Cardiac Output I:Effect of Heart Rate on Cardiac Output01:19

Cardiac Output I:Effect of Heart Rate on Cardiac Output

2.7K
Cardiac Output
Cardiac output (CO) refers to the total amount of blood ejected by one of the ventricles in liters per minute (L/min). In a resting adult, CO ranges from 5 to 6 L/min, adjusting according to the body's metabolic requirements.
Effect of Heart Rate on Cardiac Output
Cardiac output adapts to metabolic demands during stress, physical activity, or illness. The autonomic nervous system regulates heart rate via the sinoatrial node. The parasympathetic nervous system decreases heart...
2.7K
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

1.0K
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
1.0K
Anatomy of the Heart01:27

Anatomy of the Heart

119.9K
The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
119.9K
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

725
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
725
Predicting Molecular Geometry02:27

Predicting Molecular Geometry

45.9K
VSEPR Theory for Determination of Electron Pair Geometries
45.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted gene editing of <i>PCCA</i> pseudoexon using CRISPR-Cas12a for potential therapy in propionic acidemia.

Molecular therapy. Nucleic acids·2026
Same author

Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

An artefact-resilient wide bandwidth bidirectional graphene neural interface.

Nature communications·2026
Same author

Mitigating Interfacial Contamination for Scalable Integration of Graphene in Neuroelectronic Devices.

Accounts of materials research·2026
Same author

Low-temperature inkjet-printed electrochemical sensors on OSTE+ microfluidics for oxygen monitoring and scavenging.

Lab on a chip·2026
Same author

Lab-on-a-Chip Metabolic Analysis Using Benchtop NMR Technology.

Analytical chemistry·2026

Related Experiment Video

Updated: Feb 5, 2026

Generation of a Human iPSC-Based Blood-Brain Barrier Chip
10:20

Generation of a Human iPSC-Based Blood-Brain Barrier Chip

Published on: March 2, 2020

13.6K

A Tri-Culture Heart-on-a-Chip Platform With iPSC-Derived Cardiac Cells for Predictive Cardiotoxicity Testing.

Karine Tadevosyan1,2,3,4, Jose Yeste3,4, Mar Alvarez3,4

  • 1Stem Cell Potency Group, Regenerative Medicine Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet De Llobregat, Spain.

Advanced Healthcare Materials
|February 4, 2026
PubMed
Summary

A novel heart-on-a-chip platform using human cells improves drug safety testing. This advanced model better predicts cardiotoxicity by including vascular components, reducing failures in clinical trials.

Keywords:
cardiomyocytesdoxorubicin‐induced cardiotoxicityendothelial cellsinduced pluripotent stem cellsorgan‐on‐Chip

More Related Videos

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells
10:37

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells

Published on: March 14, 2021

7.4K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.2K

Related Experiment Videos

Last Updated: Feb 5, 2026

Generation of a Human iPSC-Based Blood-Brain Barrier Chip
10:20

Generation of a Human iPSC-Based Blood-Brain Barrier Chip

Published on: March 2, 2020

13.6K
Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells
10:37

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells

Published on: March 14, 2021

7.4K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.2K

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • Drug Discovery

Background:

  • High attrition rates in drug development, particularly due to cardiotoxicity, significantly increase R&D costs and timelines.
  • Current preclinical models often lack the physiological complexity, especially the vascular system, needed to accurately predict in vivo drug responses.
  • The vascular component is crucial for understanding drug distribution and its impact on cardiac health.

Purpose of the Study:

  • To develop and validate a physiologically relevant heart-on-a-chip (HoC) platform for improved cardiotoxicity assessment.
  • To integrate key cardiac cell types, including endothelial cells, to better mimic the native cardiac microenvironment.
  • To evaluate the platform's ability to predict drug-induced cardiotoxicity more accurately than conventional models.

Main Methods:

  • Developed a heart-on-a-chip (HoC) platform using a tri-culture system of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes, cardiac fibroblasts, and endothelial cells from a single genetic source.
  • Maintained cell viability (>90%) and functional maturity under perfusion for 7 days.
  • Assessed functional maturity via chronotropic responses to isoproterenol and evaluated cardiotoxicity using doxorubicin.

Main Results:

  • The tri-culture HoC system demonstrated sustained cell viability and functional maturity, responding appropriately to pharmacological stimuli.
  • The inclusion of endothelial cells in the HoC platform significantly mitigated doxorubicin-induced cardiotoxicity.
  • This protective effect, absent in conventional models, underscores the importance of the vascular component in replicating in vivo drug responses.

Conclusions:

  • The developed heart-on-a-chip platform offers enhanced physiological relevance by incorporating endothelial cells, crucial for accurate cardiotoxicity assessment.
  • This scalable platform represents a transformative tool for improving preclinical drug safety evaluation and potentially reducing animal testing.
  • The findings highlight the critical role of vascular integration in predicting drug-induced cardiac adverse events.